Illumina offers understanding of molecular mechanisms

San Diego-based Illumina is commercializing three new products aimed at a better understanding of the molecular mechanisms that give rise to cancer. Illumina's DASL Assay is designed to profile expression in degraded RNA, such as that found in formalin-fixed paraffin embedded samples. At the Dana-Farber Cancer Institute researchers are using whole-genome DASL profiling to identify molecular profiles associated with chemotherapy resistance in ovarian cancer.

"We have a significant number of archived ovarian cancer samples, and this new approach has provided me with a way to finally access the information in these invaluable samples," said Harvard's Dr. John Quackenbush. "The DASL assay gives us the ability to obtain consistent, high-quality data from FFPE samples and has opened-up new avenues of investigation that were not previously available to us."

- check out the press release
- read the story in Forbes

Related Articles:
Illumina focuses on molecular diagnostics. Illumina report
Four companies lead genome sequencing race. Illumina report
Illumina to buy Solexa for $600M. Illumina report

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.